These findings indicate that, although COX-2 inhibitors have anti-inflammatory benefits, etoricoxib may be harmful as an adjunct therapy in TB, potentially weakening key immune functions, especially macrophage-mediated bacterial control [91]. This evidence concerns the gene PTGS2 and tuberculosis.